Loading...
  • kinase
  • Lapatinib is one of a new class of drugs called "oral dual kinase inhibitors," which block the ErbB-1 and ErbB-2 receptors. (drugs.com)
  • In this study, we compared the effects of SKI-606 with Iressa, Src/Abl and EGF-R kinase inhibitors, respectively, on selected parameters in HeLa and SiHa cervical cancer cell lines, which express E6/E7 oncoproteins of high-risk HPV types 18 and 16, respectively. (hindawi.com)
  • clinical
  • To date, numerous prognostic factors for the treatment of breast cancer have been identified based on clinical and pathological features. (turkjsurg.com)
  • Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. (springer.com)
  • the changes of these objective markers may be useful in evaluating the clinical response of neo-adjuvant chemotherapy in breast cancer. (biomedsearch.com)
  • Women (n = 74) with clinical stage II or III breast cancer were enrolled in this open-label, multicenter study to receive six 2-weekly courses of gemcitabine 1000 mg/m2 plus docetaxel 75 mg/m2 on days 1 and 15, and vinorelbine 25 mg/m2 plus epirubicin 100 mg/m2 on days 29 and 43. (nih.gov)
  • breast cancer is that of designing new combination chemotherapies in which the best drugs already available are used together with new anticancer agents devoid of clinical cross-resistance. (bioportfolio.com)
  • To evaluate the clinical importance of LIF in breast cancer, a cohort of 374 breast cancer patients was employed. (amazonaws.com)
  • The secondary aims include determination of the pCR rate in breast only, clinical complete response (cCR) rate, two-year recurrence-free interval, two-year overall survival, toxicity of the neoadjuvant regimens, and exploration of molecular and genetic correlates of response. (bioportfolio.com)
  • The role of the progesterone receptor (PR) in breast cancer remains a major clinical challenge. (sigmaaldrich.com)
  • Recurrence
  • DURHAM, N.C., August 02, 2007 /PRNewswire/ -- Some practical recommendations can aid in managing adverse reactions to lapatinib (Tykerb) -- a new drug that improves the outcomes of treatment for breast cancers with certain mutations linked to a high risk of recurrence -- according to an article in the July issue of "The Oncologist. (drugs.com)
  • Recurrence-free survival in patients with breast cancer without a pathologic complete response after neoadjuvant treatment with gemcitabine plus docetaxel alternating with vinorelbine plus epirubicin according to triple-negative status. (nih.gov)
  • Presence of cancer cells in blood- and lymph vessels close to the tumour in patients with grade 3 tumours increased the risk oflocoregional recurrence 6-fold as compared to patients with grade 1 or 2 tumours without such vascular invasion. (diva-portal.org)
  • Disease-free interval and survival in patients with distant recurrence were strongly associated to histologic grade and hormone receptor content. (diva-portal.org)
  • Patients with grade 3, hormone receptor negative tumours had a median survival of 10 months after recurrence while only 15 % of women with receptor positive, grade 1 tumours have so far died after a median follow-up time of 5 years after recurrence. (diva-portal.org)
  • metastasis
  • Breast cancer as a systemic disease: a view of metastasis. (springer.com)
  • To directly investigate the effect of LIF on metastasis in breast cancer, two chamber trans-well assays were employed to determine the effects of LIF on the abilities of invasion and migration of MDA-MB-231, MCF7 and T47D cells. (amazonaws.com)
  • In addition to promoting metastasis, LIF also promoted proliferation of breast cancer cells. (amazonaws.com)
  • To further determine whether the activation of AKT-mTOR pathway contributes to the effect of LIF on breast cancer tumorigenesis and metastasis, above-mentioned breast cancer cell lines were treated with LIF along with or without wortmannin to block AKT pathway. (amazonaws.com)
  • Figure 6: Blocking the AKT signaling inhibits the promoting effect of LIF on tumorigenesis and metastasis in breast cancer cells. (amazonaws.com)
  • Results from this study demonstrate that LIF promotes the growth and metastasis of breast cancer. (amazonaws.com)
  • It is currently unclear whether LIF activates the AKT-mTOR pathway to promote tumorigenesis and metastasis in other types of cancers. (amazonaws.com)
  • In summary, results from this study demonstrate that LIF plays a vital role in promoting growth and metastasis of breast cancer. (amazonaws.com)
  • We previously reported that α -mangostin significantly inhibits both tumor growth and metastasis in a mouse model of mammary cancer [ 9 , 10 ]. (hindawi.com)
  • ovarian-cancer
  • Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. (springer.com)
  • Inhibitors
  • 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4. (nih.gov)
  • implications
  • The potential for the targeted inactivation of cell surface proteins by a gene therapy approach has implications for the treatment of many human diseases including cancer and viral infections. (springer.com)
  • Hormone receptor status has major implications for treatment and survival of breast cancer. (springer.com)
  • proteins
  • 2. The growing availability of cancer drugs that target receptors and other signaling proteins has created a need to develop integrated methods for best matching of patients to the appropriate target drugs. (yale.edu)
  • human
  • Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. (springer.com)
  • Our findings indicate that SKI-606 inhibits signaling pathways involved in regulating tumor cell migration and invasion genes via -catenin alteration, suggesting that Src inhibitor, in comparison to EGF-R, is a promising therapeutic agent for human cervical cancer. (hindawi.com)
  • Important etiological factors in the development of this cancer are human papillomaviruses (HPVs), as more than 96% of cervical cancers are positive for high-risk HPVs especially types 16, 18, 31, 33, and 35 [ 1 - 3 ]. (hindawi.com)
  • Human cervical cancers are characterized by a marked propensity for invasion and spreading to local lymph nodes. (hindawi.com)
  • specimens
  • The final surgical specimens were obtained from patients with breast carcinoma who received neo-adjuvant chemotherapy and obtained a partial response (PR). (biomedsearch.com)
  • In addition, the change expressions of C-erbB-2 and CXCR4 in specimens tended to be correlated with pathological change to neo-adjuvant chemotherapy on full tissue sections and on TMAs in a Pearson chi-square analysis. (biomedsearch.com)
  • constitutively
  • In NIH/3T3 fibroblasts transformed by a mutated, constitutively active erbB-2, scFv-mediated intracellular retention of erbB-2 led to complete reversion of the transformed phenotype. (springer.com)
  • The E6 and E7 oncoproteins of high-risk HPVs, which are constitutively expressed in these cancers, inactivate p53 and pRb tumour suppressors, respectively [ 8 ]. (hindawi.com)